Budesonide showed no clear difference in remission (combined clinical and endoscopic remission) compared with mesalamine (low certainty).
Budesonide showed no clear difference in clinical improvement compared with mesalamine (moderate certainty).
Budesonide showed no clear difference in serious adverse events compared with mesalamine (low certainty).
Budesonide showed no clear difference in serious adverse events compared with mesalazine (low certainty).
Budesonide may leads to higher clinical response sensitivity analysis excluding Miehlke 2014 compared with placebo (low certainty).
Budesonide may leads to higher histological response sensitivity analysis excluding Miehlke 2014 compared with placebo (low certainty).
Budesonide may leads to higher maintenance of clinical response compared with placebo (low certainty).
It is very uncertain whether budesonide changes maintenance of histological response compared with placebo (very low certainty).
Budesonide showed no clear difference in adverse events compared with placebo (low certainty).
It is very uncertain whether budesonide changes withdrawals due to adverse events compared with placebo (very low certainty).
It is very uncertain whether budesonide changes serious adverse events compared with placebo (very low certainty).
Budesonide may leads to higher clinical response compared with mesalazine (low certainty).
Budesonide may leads to higher histological response compared with mesalazine (low certainty).
Budesonide showed no clear difference in adverse events compared with mesalazine (low certainty).
Budesonide showed no clear difference in withdrawals due to adverse events compared with mesalazine (low certainty).
Budesonide may leads to higher clinical response compared with mesalazine (low certainty).
Budesonide may leads to higher histological response compared with mesalazine (low certainty).
Budesonide showed no clear difference in adverse events compared with mesalazine (low certainty).
Budesonide 3 mg showed no clear difference in induction of clinical remission (CDAI < 150) ‐ 8 weeks compared with placebo (low certainty).
Budesonide 3 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).